In Business news

Follow this topic

Bookmark

Record learning outcomes

The MHRA has eased the cold chain transport requirements for Wegovy, which can now be kept at temperatures of up to 30 degrees Celsius for up to 48 hours between when it arrives in the UK and when it reaches its destination. 

Previously, the drug was required to be stored at 2-8 degrees Celsius at all points in the distribution pathway. 

The updated product information for Wegovy FlexTouch was announced on Thursday April 23, making it the first injectable GLP-1 weight management product to obtain approval from the medicines regulator for less stringent delivery requirements. 

It follows a similar update from the European Medicines Agency on April 12. 

Manufacturer Novo Nordisk said: “In the UK there is increasing adoption of direct-to-patient distribution models, including delivery through online pharmacies and other non-traditional dispensing channels.

“The reduced dependence on cold chain transport for Wegovy is expected to lessen the environmental footprint by reducing packaging volume and weight, as well as providing new delivery options for pharmacies and online partners.”

Novo Nordisk UK general manager Sebnem Avsar Tuna added: “Across the UK, pharmacists and other healthcare providers are increasingly using direct delivery of medicines to patients’ homes. 

“We welcome the approval by the MHRA, which will help these providers reduce delivery complexities, supporting efficiencies and sustainability in the final stage of delivery to patients.”